The preventive administration of p62 in the young (3 months) OXYS rats demonstrated an efficacy in blocking the advancement of the disease, while the p62 therapeutic use in the aged OXYS group reversed the AMD-like retinopathy and alleviated the pathological scenario. This evidence concerns the gene SQSTM1 and age-related macular degeneration.